
    
      A Phase II, Single-arm, Multi-centre Study of Durvalumab as Sequential Therapy in Patients
      with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not
      Progressed Following Rh-Endostatin combined with reduced-dose CCRT(50 Gy) Therapy (Relief)
    
  